Management of difficult to treat locations of psoriasis: Scalp, face, flexures, palm/soles and nails

Current Problems in Dermatology

Volumn 38, Issue , 2009, Pages 160-171

  Kragballe, Knud ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID; DITHRANOL; KERATOLYTIC AGENT; SALICYLIC ACID; VITAMIN D DERIVATIVE;

CLINICAL ASSESSMENT; CLINICAL FEATURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PSORIASIS; REMISSION; REVIEW; TREATMENT INDICATION; X RAY; FACE; FOOT; GENITAL SYSTEM; HAND; NAIL; PATHOLOGY; SCALP;

FACE; FOOT; GENITALIA; HAND; HUMANS; NAILS; PSORIASIS; SCALP;

EID: 70350501147     PISSN: 14215721     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000232309     Document Type: Review

References (45)

1. Finlay AY: Current severe psoriasis and the rule of tens. Br J Dermatol 2005;152:861-867.
2. Pauporte M, Maibach H, Lowe N, et al: Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatol Treat 2004;15:360-364.
3. Stein L: Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis: J Am Acad Dermatol 2005;53(suppl 1): S39-S49.
4. Gottlieb AB, Ford RO, Spellman MC: The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003;7:185-192.
5. Andreassi L, Giannetti A, Milani M, Scalp Investigators Group: Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients: Br J Dermatol 2003;148:134-138.
6. Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V: Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004;3:367-373.
7. Ruzicka T, Trompke C: Treatment of scalp psoriasis: an effective and safe tacalcitol emulsion. Hautarzt 2004;55:165-170.
8. Barnes L, Altmeyer P, Forstrom L, Stenstrom MH: Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000;10: 199-204.
9. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, Abdullah SA: Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 1% lotion. Int J clin Pharmacol Res 2000;20:483-487.
10. Jemec GBE, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno, Berne B, Figueiredo A, Anstad J: A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind controlled trial. J Am Acad Dermatol 2008;59:455-463.
11. Luger T, Kidson P, Cambazard F, Larsen FG: A 1-year randomized, double-blind safety study of long-term treatment of a new gel formulation containing calcipotriene plus betamethasone dipropi-onate in scalp psoriasis. J Am Acad Dermatol 2008; 58 (suppl 2):AB134.
12. Langer A, Wolska H, Hebborn P: Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis 1983;32:295-296.
13. Wulff-Woesten A, Ohlendorf D, Henz BM, Hass N: Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol 2004;17:91-97.
14. Lindelof B: Grenz ray therapy in dermatology: an experimental, clinical and epidemiological study. Acta Derm Venereol Suppl (Stockh) 1987;132:1-67.
15. Park JY, Kim JH, Choe YB: Facial psoriasis: Comparison of patients with and without facial involvement. J Am Dermatol 2004;50:582-584.
16. Tadaki T, Kato T, Tagami H: Topical active vitamin D-3 analogue, 1,24-dihydroxycholecalciferol, an effective new treatment for facial seborrhoeic dermatitis. J Dermatolog Treat 1996;7:139-140.
17. Langer A, Stapor V, Verjans H, Elzerman J: Calcitriol ointment in the treatment of facial, hairline and ret-roauricular chronic plaque psoriasis. J Dermatolog Treat 1996;7:(suppl I):S15-S18. (Pubitemid 26288477)
18. Kienbaum S, Lehmann P, Ruzicka T: Topical calci-potriol in the treatment of flexural psoriasis. Br J Dermatol 1996;135:647-650.
19. Ortonne JP, Humbert P, Nicolas JF, Tsankov N, Tonev SD, Janin A, et al: Intraindividual comparison of the cutaneous safety and efficacy of calcitriol 3 mcg g-1 ointment and calcipotriol 50 mcg g-1 ointment on chronic plaque psoriasis localized in facial, hairline, retroauriculair or flexural areas. Br J Dermatol 2003;148:326-333.
20. Lebwohl M, Freeman A, Chapman MS, Feldman SR, Hartle JE, Henning A: Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51:723-730.
21. Jacobi A, Braetigam, Mahler V, Schultz E, Herti M: Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology 2008;216:133-136.
22. Kleyn CE, Woodcock D, Sharpe GR: The efficacy of 0.1% tacrolimus ointment compared with clobeta-sonebutyrate 0.05% ointment in patients with facial flexural or genital psoriasis (abstract). Br J Dermatol 2005;153(suppl 1):33.
23. Gribetz C, Ling M, Lebwohl M, Pariser D, Draelos Z, Gottlieb AB, Zaias N, Chen DM, Parneix-Spake A, Hultsch T, Menter A: Picmecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-738.
24. Kreuter A, Sommer A, Hyun J, Brautigam M, Brockmeyer NH, Altmeyer P, Gambichler T: 1% pimecrolimus, 0.005% calcipotriol, and 0.1%betame-thasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006;142:1138-1143.
25. Griffiths CEM, Christophers E, Barker JNWN, Chalmers RJG, Chimenti S, Krueger GG, Leonardi C, Menter A, Ortonne J-P, Fry L: A classification of psoriasis vulgaris according phenotype. Br J Dermatol 2007;156:258-262.
26. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman S: Patients with palmo-plantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003;49: 271-275.
27. Yiannias JA, Winkelmann RK, Connolly SM: Contact sensitivities in palmo-plantar pustulosis. Contact Dermatitis 1998;39:108-111.
28. Kragballe K, Larsen FG: A hydrocolloid occlusive dressing plus triamcinolone acetonide cream is superior to clobetasol cream in palmo-plantar pus-tulosis. Acta Derm Venereol 1991;71:540-542.
29. Duweb GA, Abuzariba O, Rahim M, al-Taweel M, al-Alem S, Abdulla SA: Occlusive versus nonocclu-sive calcipotriol ointment treatment for palmoplan-tar psoriasis. Int J Tissue React 2001;23:59-62.
30. Lassus A, Greiger JM: Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988;119:755-759.
31. Jansen CT, Malmiharju T: Inefficacy of topical methoxalen plus UVA for palmoplantar pustulosis. Acta Derm Venereol 1981;61:354-356.
32. De Rie MA, Van Eendenburg JP, Versnick AC, Stolk LM, Bos JD, Westerhof W: A new psoralen-contain-ing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema. Br J Dermatol 1995;132:964-969.
33. Aubin F, Vigan M, Puzenat E, et al: Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: a pilot study in different chronic localized dermatoses. Br J Dermatol 2005; 152:99-103.
34. Erkko P, Granlund H, Remitz A, et al: Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustu-losis. Br J Dermatol 1998;139:997-1004.
35. Leonardi C, Sofen H, Krell J, Caro I, Compton P, Sobell JM: Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot plaques psoriasis. J Am Acad Dermatol 2007; 56(suppl 2), AB84, poster 532.
36. Fretzin S, Crowley J, Jones L, Young M, Sobell J: Successful treatment of hand and foot psoriasis with efalizumab therapy. J Drugs Dermatol 2006;5:838-846.
37. de Jong EM, Seegers BA, Gulinck MK, Boezemann JB, van de Kerkhof PC: Psoriasis of the nails is associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996;193:300-303.
38. Piraccini BM, Trosti A, Iorizzo M, Misciali C: Pustular psoriasis of the nails: treatment and long-term follow-up of 46 patients. Br J Dermatol 2001; 144:1000-1005.
39. Tosti A, Piraccini BM, Cameli N, et al: Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998;139:655-659.
40. de Berker DA, Lawrence CM: A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998;138:90-95.
41. Bleeker JJ: Intralesional triamcinolone acetonide using the Port-O-Jet and needle injections in localized dermatoses. Br J Dermatol 1997;91:97-101.
42. Rigopoulos D, Ioannides D, Prastitis N, Katsambas A: Nail psoriasis: a combined treatment using calci-potriol cream and clobetasol propionate cream (letter). Acta Derm Venereol 2002;82:140.
43. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK: Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail and joint involvement. J Am Acad Dermatol 1995;32:78-88.
44. Feliciani C, Zampetti A, Forleo P, et al: Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg 2004;8: 122-125.
45. Rich P, Griffiths CEM, Reich K, Nestle F, Scher RK, Li S, Xu S, Hsu M-C, Guzzo C: Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58:224-231.